Dernière mise à jour :
29/10/2024
Immunosuppresseur   Tacrolimus  
Solution buvable
Collyre injectable
Stabilité des préparations Stabilité en mélange Facteur influençant la stabilité Compatibilités Bibliographie pdf
   Structure chimique  

Solution buvable
Bibliographie   Solution buvable   Bibliographie : Tacrolimus  
Type Source
2436 Revue Jacobson PA, Johnson CE, West NJ, Foster JA.
Stability of tacrolimus in an extemporaneously compounded oral liquid
Am J Health-Syst Pharm 1997 ; 54: 178-180.
2789 Revue Elefante A, Muindi J, West K, Dunford L, Abel S, Paplham P, Brown K, Hahn T, Padmanabhan S, Battiwalla M, McCarthy PL.
Long-term stability of a patient-convenient 1mg/ml suspension of tacrolimus for accurate maintenance of stable therapeutic levels.
Bone Marrow Transplantation 2006 ; 37, 8: 781-784.
3846 Revue Polonini HC, Silva SL, Cunha CN, Brand?o MAF, Ferreira AO.
Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, lorazepam, minocycline hydrochloride, tacrolimus monohydrate, terbinafine, tramadol hydrochloride and valsartan in SyrSpend® SF PH4 oral suspensions.
Pharmazie 2016 71: 185?191.
3946 Revue Friciu M, Zaraa S, Leclair G.
Stability of Extemporaneously Compounded Tacrolimus in Glass Bottles and Plastic Syringes
Can J Hosp Pharm 2017 ; 70,1 :51-53.
4177 Revue Polonini H, Loures da Silva S, Fernandes Brandao M.A, Bauters T, De Moerloose B, De Oliveira Ferreira A.
Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF PH4.
Int J Pharm Compound 2018 ;22,6:516-526
4673 Revue Barrieu M, Chennell P, Yessaad M, Bouattour Y, Wasiak M, Jouannet M, Le Basle Y, Sautou V.
Physicochemical Stability of a Novel Tacrolimus Ophtalmic Formulation for the Treatment of Ophtalmic Inflammatory Diseases.
Pharmaceutics 2022 ;14,1:118

  Mentions Légales